Trial
NCT02439138
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Dana-Farber Cancer Institute
Collaborators
Gilead Sciences
Condition
Waldenstrom's Macroglobulinemia
Intervention
GS-1101
Why stopped
Safety issues from trials in CLL
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-01-11